WA Medical Researchers to Benefit from Expanded Lab Facilities: A Collaboration for Innovation and Improved Patient Outcomes
Western Australia's medical research landscape is set to undergo a significant transformation with the expansion of lab facilities at RAPID Labs, located at Sir Charles Gairdner Hospital. This ambitious project, a collaborative effort between various institutions, promises to enhance the state's capacity for molecular imaging and radiopharmaceutical research, ultimately improving patient care and outcomes.
A Collaboration for Shared Research Capability
The project is a testament to the power of collaboration between universities, hospitals, government bodies, and national research infrastructure providers. The Western Australia Node of the National Imaging Facility (WA NIF), The University of Western Australia (UWA), RAPID Labs, the Department of Health, the National Imaging Facility through the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS), and a range of philanthropic and research partners have joined forces to create a shared research capability.
UWA Deputy Vice-Chancellor (Research) Professor Anna Nowak emphasizes the importance of this partnership, stating, "This project highlights what can be achieved when institutions work together to build shared research capability. The integration of RAPID Labs and WA NIF infrastructure creates a powerful platform for innovation that will support researchers across multiple disciplines, including cancer, cardiovascular disease, and neurological research."
Enhancing Research Capabilities and Patient Access
The expanded facility includes a second cyclotron and new radiopharmaceutical laboratories, significantly increasing local production capacity for radiopharmaceuticals used in PET and SPECT imaging. These radiopharmaceuticals are crucial for diagnosing and treating various conditions, such as cancers, Alzheimer’s disease, dementia, epilepsy, stroke, Parkinson’s disease, heart diseases, and thyroid disorders.
WA NIF and UWA have funded and established a dedicated research radiopharmaceutical laboratory within the new facility, providing researchers with access to advanced infrastructure to support the development and translation of new imaging agents and therapies. This "bench-to-bedside" approach accelerates the translation of research into improved patient outcomes.
Professor Paul M Parizel, WA NIF Node Director, highlights the importance of this collaboration: "Researchers will have greater access to the radiopharmaceuticals and imaging technologies needed to support discovery research, preclinical studies, and clinical trials, helping accelerate the translation of research into improved patient outcomes. This collaboration brings together radiopharmaceutical production, imaging infrastructure, and research expertise in a way that will significantly strengthen Western Australia’s health and medical research ecosystem."
Addressing Supply and Demand for Radiopharmaceuticals
The expansion is expected to improve opportunities for WA-based researchers to recruit patients for national and international clinical trials. Currently, many radiopharmaceuticals required for clinical trials must be transported from interstate due to Good Manufacturing Practice (GMP) requirements, limiting access and participation opportunities for WA patients and researchers.
The new infrastructure will also support WA’s only preclinical PET-SPECT-CT imaging capability, enabling researchers to test new diagnostic and therapeutic radiopharmaceuticals before progressing into human studies. This capability is crucial for advancing personalized medicine, targeted therapies, and precision imaging.
A Global Perspective on Radiopharmaceutical Demand
The demand for radiopharmaceuticals continues to grow globally, driven by advances in personalized medicine, targeted therapies, and precision imaging. The expanded infrastructure at SCGH and the Queen Elizabeth II Medical Centre precinct positions Western Australia to support growing research demand while strengthening local capability in molecular imaging and radiopharmaceutical science.
Conclusion: A Catalyst for Innovation and Patient Care
The project has been supported through contributions from UWA, NIF, the Department of Health, the Ian Potter Foundation, Stan Perron Foundation, Lotterywest, Cancer Council WA, Perron Institute, Curtin University, Edith Cowan University, Harry Perkins Institute of Medical Research, and Murdoch University. This collaboration is a catalyst for innovation in medical research, with the potential to significantly improve patient care and outcomes in Western Australia and beyond.
